Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of taletrectinib in adult Japanese patients
jRCT2071210109Active, not recruiting
- Sponsor
- Nuvation Bio
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of taletrectinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Nuvation Bio. Primary endpoints: Safety endpoints and Efficacy endpoints. Started Dec 2021; status: active, not recruiting.
02
Drugs
taletrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071210109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210109.